Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
901-920 of 991 trials

Idiopathic Membranous Nephropathy: AP1189 Study

We are exploring whether the medication AP1189 can improve kidney function and reduce protein in urine for patients with idiopathic membranous nephropathy. This study involves patients already receiving ACE inhibitors or angiotensin II receptor blockers.

Membranous Nephropathy1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

STOP-LEUKEMIA: Metformin for Blood Disorders

We are investigating whether metformin can help prevent leukemia in patients with clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes. This study will assess the safety of metformin and explore how it may affect disease progression.

Myelodysplastic Syndromes (MDS)Clonal Cytopenia of Undetermined Significance (CCUS)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Heart Failure: PF-07328948 Study

We are testing a new oral medication for adults with heart failure to see if it improves heart function and symptoms compared to a placebo. The study also examines the safety of this treatment.

Heart Failure6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Kidney Disease: Vicadrostat and Empagliflozin Study

We are investigating whether starting vicadrostat with empagliflozin helps people with chronic kidney disease. The study compares two different ways of starting the medications to see which is more effective.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteDiabetologyNephrology

Immune Thrombocytopenia: Pirtobrutinib Study

We are investigating a new medication, pirtobrutinib, for adults with immune thrombocytopenia. The study aims to assess its safety and effectiveness compared to a placebo.

Immune Thrombocytopenia≤3 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteHematology

Glaucoma: Oral Semaglutide Study

We are investigating whether oral semaglutide can safely improve retinal function in patients with open-angle glaucoma. This research may help find new ways to protect vision in those affected by this condition.

Glaucoma>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyOphthalmology

Lung Cancer Treatment: Telisotuzumab Adizutecan with Osimertinib

We are studying a new combination treatment for adults with advanced EGFR-mutated non-small cell lung cancer. The goal is to see if this approach is safer and more effective than current standard treatments.

Non-Small Cell Lung Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Ulcerative Colitis: MK-7240 Treatment Study

We are studying MK-7240 to see if it helps people with moderately to severely active ulcerative colitis achieve remission. The trial will also evaluate the safety and effectiveness of this new treatment compared to a placebo.

Ulcerative Colitis1-2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterology

Schizophrenia and Alcohol Use Disorder: Tirzepatide Study

We are investigating whether tirzepatide can help reduce alcohol consumption in individuals with schizophrenia and alcohol use disorder. This study compares tirzepatide to a placebo to assess its effects.

Schizophrenia and Alcohol Use Disorder6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyPsychiatry

Erosive Esophagitis: Linaprazan Glurate vs. Lansoprazole

We are studying whether linaprazan glurate can heal erosive esophagitis in patients with GERD better than lansoprazole. This trial aims to evaluate the effectiveness and safety of the new treatment.

Erosive Esophagitis≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Apathy After Stroke: Brain Pathway Study

We are examining how cholinergic and dopaminergic systems relate to apathy in stroke patients. This study aims to understand the brain's role in apathy to improve future treatments.

ApathyStroke>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Patritumab Deruxtecan for Pediatric Solid Tumors

We are studying a new treatment for children with relapsed or refractory solid tumors to see if it is safe and effective. This trial aims to understand how well it works compared to existing options.

HepatoblastomaRhabdomyosarcoma>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesCost ReimbursementOncologyPediatrics

Peyronie's Disease: FAPI-PET/CT and FDG-PET/CT Scans

We are investigating whether special imaging scans can detect inflammation and active tissue changes in men with acute Peyronie's Disease. This may help improve diagnosis and treatment options.

Peyronie's Disease6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementOtolaryngologyUrology

Ulcerative Colitis and Crohn’s Disease: Long-term Study of Zasocitinib

We are investigating the long-term safety and effectiveness of oral zasocitinib in adults with moderately to severely active ulcerative colitis and Crohn’s disease. This study is for those who have responded to treatment in previous trials.

Ulcerative ColitisCrohn's Disease>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Narcolepsy and Idiopathic Hypersomnia: ORX750 Study

We are testing a new medication, ORX750, to see if it is safe and well-tolerated in people with narcolepsy and idiopathic hypersomnia. This study will help us understand how the drug works in the body.

Narcolepsy with CataplexyIdiopathic Hypersomnia3-6 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Worsening Heart Failure: COR-1167 Treatment Study

We are testing a new medication for people with worsening heart failure to see how it affects symptoms and heart health. The study will also check the safety and tolerability of this treatment.

Worsening Heart Failure≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Chronic Graft-Versus-Host Disease: Axatilimab Treatment Study

We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.

Chronic Graft-Versus-Host Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

X-ALD: Pramipexole for Leg Symptoms

We are investigating whether pramipexole can help reduce restless leg symptoms in women with X-linked Adrenoleukodystrophy. This study aims to improve their sleep and walking performance.

X-linked AdrenoleukodystrophyRestless Legs Syndrome3-6 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurology

Ulcerative Colitis: Comparing Risankizumab and Vedolizumab

We are studying whether risankizumab is more effective and safe than vedolizumab for adults with moderate to severe ulcerative colitis who have not yet received targeted treatments.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Chronic Heart Failure: Ferric Derisomaltose Treatment

We are studying whether ferric derisomaltose can improve heart health and reduce hospitalizations in people with iron deficiency and chronic heart failure. This trial compares it to no intravenous iron treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine